⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL27440507 | 0.73 | — | — | |
| SCHEMBL5735436 | 0.71 | — | — | |
| SCHEMBL355884 | 0.71 | — | — | |
| Fluoride SCHEMBL27758166 | 0.67 | — | — | |
| SCHEMBL487551 | 0.62 | — | — | |
| Propene SCHEMBL1737 | 0.59 | — | — | |
| SCHEMBL25300799 | 0.58 | — | — | |
| SCHEMBL1458221 | 0.58 | — | — | |
| SCHEMBL166729 | 0.58 | — | — | |
| SCHEMBL6258387 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218633-A1 | METHODS OF TREATING ORAL MUCOSITIS | GALERA LABS, LLC | 2023-07-13 | — | — | US | disclosed |
| US-20230114671-A1 | NUCLEOSIDE ANALOGUE, PREPARATION METHOD AND APPLICATION | GENEMIND BIOSCIENCES COMPANY LIMITED (CN) | 2023-04-13 | — | — | US | disclosed |
| US-11612608-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2023-03-28 | — | — | US | disclosed |
| US-11512106-B2 | Nucleoside analogue, preparation method and application | GENEMIND BIOSCIENCES COMPANY LIMITED (CN) | 2022-11-29 | — | — | US | disclosed |
| EP-3733683-A1 | NUCLEOSIDE ANALOGUE, PREPARATION METHOD AND APPLICATION | GeneMind Biosciences Company Limited (CN) | 2020-11-04 | — | — | EP | disclosed |
| CN-111741967-A | Nucleoside analogue, preparation method and application | 深圳市真迈生物科技有限公司 | 2020-10-02 | — | — | CN | disclosed |
| US-20200283467-A1 | NUCLEOSIDE ANALOGUE, PREPARATION METHOD AND APPLICATION | GENEMIND BIOSCIENCES COMPANY LIMITED (CN) | 2020-09-10 | — | — | US | disclosed |
| US-20200215077-A1 | METHODS OF TREATING ORAL MUCOSITIS | BIOSSIL INC. (CA) | 2020-07-09 | — | — | US | disclosed |
| US-10610533-B2 | Methods of treating oral mucositis | GALERA LABS, LLC (US) | 2020-04-07 | — | — | US | disclosed |
| EP-3527079-A1 | METHODS OF TREATING ORAL MUCOSITIS | Galera Labs, LLC (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-0598753-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1994-06-01 | — | — | EP | disclosed |
| WO-1993002090-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1993-02-04 | — | — | WO | disclosed |
| EP-0524161-A1 | Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide | MONSANTO COMPANY (US) | 1993-01-20 | — | — | EP | disclosed |
| EP-0204285-B1 | IMIDAZOHETEROCYCLIC COMPOUNDS PROCESSES FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-01-15 | — | — | EP | disclosed |
| EP-0339071-A1 | IMIDAZO(1,2-a)(PYRIDAZINES OR PYRAZINES) FOR TREATMENT OF DISEASES RELATED TO BONE LOSS | Aktiebolaget Hässle (SE) | 1989-11-02 | — | — | EP | disclosed |
| WO-1989003833-A1 | IMIDAZO(1,2-a)(PYRIDAZINES OR PYRAZINES) FOR TREATMENT OF DISEASES RELATED TO BONE LOSS | Aktiebolaget Hässle (SE) | 1989-05-05 | — | — | WO | disclosed |
| US-4725601-A | Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-02-16 | — | — | US | disclosed |
| CN-86104313-A | The preparation method of Imidazoheterocyclic compounds | — | 1987-03-04 | — | — | CN | disclosed |
| EP-0204285-A1 | Imidazoheterocyclic compounds processes for preparation thereof and pharmaceutical compositions comprising them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1986-12-10 | — | — | EP | disclosed |
| US-4556415-A | POST-EMERGENCE | MONSANTO COMPANY (US) | 1985-12-03 | — | — | US | disclosed |